US Patent Issued to City of Hope, Imugene on Aug. 4 for "Methods comprising oncolytic viruses expressing CD19T and bispecific T cell engagers" (American, Australian Inventors)

ALEXANDRIA, Va., Aug. 5 -- United States Patent no. 12,698,512, issued on Aug. 4, was assigned to City of Hope (Duarte, Calif.) and Imugene Ltd. (Sydney).

"Methods comprising oncolytic viruses expressing CD19T and bispecific T cell engagers" was invented by Saul J. Priceman (Valley Village, Calif.), Anthony K. Park (Pomona, Calif.), Yuman Fong (Pasadena, Calif.) and Monil Shah (Sydney).

According to the abstract* released by the U.S. Patent & Trademark Office: "Described herein, inter alia, are oncolytic viruses expressing a truncated human CD19 (CD19t) and methods for treating a patient suffering from a solid tumor by administering an oncolytic virus expressing truncated human CD19 (OV19t), and optionally a T cell engager targeted to CD1...